Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial.
Nuri B HasbalGregory G SchwartzStephen J NichollsKevin A BuhrHenry N GinsbergJan O JohanssonEwelina KulikowskiKenneth LebiodaPeter P TothNorman WongMichael SweeneyKausik K Raynull nullPublished in: Clinical journal of the American Society of Nephrology : CJASN (2021)
Apabetalone may reduce the incidence of major adverse cardiovascular events in patients with CKD and type 2 diabetes who have a high burden of cardiovascular disease.
Keyphrases
- cardiovascular events
- cardiovascular disease
- type diabetes
- acute coronary syndrome
- randomized controlled trial
- chronic kidney disease
- risk factors
- glycemic control
- study protocol
- coronary artery disease
- cardiovascular risk factors
- percutaneous coronary intervention
- antiplatelet therapy
- insulin resistance
- clinical trial
- skeletal muscle
- atrial fibrillation
- drug induced
- electronic health record